The therapeutic landscape of atopic dermatitis changed tremendously in the previous decade. Novel insights into the pathogenesis enabled researchers to find important targets for therapy. With regard to topical therapy, novel hyperselective phosphodiesterase-4 blockers show promising results.
Increased cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity in peripheral blood leukocytes is associated with the immune and inflammatory hyperreactivity that characterises atopic dermatitis (AD). PDE inhibitors exert an anti-inflammatory action by increasing the intracellular cAMP concentration, inhibiting the production of inflammatory cytokines (interferon-gamma, TNF-alpha, IL-4, IL-12, IL-17a, and IL-23) and other inflammatory mediators. “Difamilast is a novel hyperselective PDE-4B Blocker that looks really promising,” said Prof. David Cohen (New York University School of Medicine, USA) . In animal models, PDE-4B turned out to be a key regu...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Novel anti-IgE drug enables durable urticaria control Next Article
Oral antibiotics for acne treatment »